Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Bibliographic Details
Main Authors: Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Format: Online
Language:English
Published: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128890/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128890/

Similar Items